This is an adaptation of my March 2026 case conference on the same patient, reworked for a shared WVU–Jamaica teleconference with a mostly resident and generalist audience. Ages, dates and other identifying details have been changed.
The talk opens with why measles matters now, given 2026 activity in the Americas, Jamaica and West Virginia. It then reviews measles basics and what the MMR vaccine is. The case is a woman who developed body aches without fever, a runny nose and a spreading maculopapular rash 13 days after MMR, framed from the perspective of the first clinician to see her. It covers what to tell a patient who calls ahead and how to keep a suspected case out of the waiting room.
The discussion follows the question of whether MMR can “cause measles.” The answer runs through the expected post-vaccine fever and rash, the Finnish twin trial on timing, and how measles moves through the body. That last section explains why the prodrome tracks epithelial infection while the rash tracks the immune response. A brief comparison with dengue, Zika and chikungunya rashes follows. Outbreak data from Minnesota and China show how VARI and wild-type measles differ (the 3 Cs, Koplik spots, exposure history) and where they overlap. The talk ends with what to collect at the first visit and why only vaccine-specific PCR or genotyping can settle the question.
The talk includes live Mentimeter polls. The deck was revised with help from Claude (Anthropic); I chose the content and case, revised the slides, and am responsible for the citations and accuracy.